Arca
Skip to content
Tools
Tools

Eosinophilic asthma

Drug research and approvals for eosinophilic asthma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 15 studies of eosinophilic asthma are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 15
  • Trials authorized in Canada: 12
  • FDA orphan approvals: 0
  • EU medicines: 3

Recruiting now

Newest posted first, of 15 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 12; search them all in Canada trials
May 13, 2025An open-label long-term phase III extension study to assess the long-term safety and tolerability of dexpramipexole in participants with severe eosinophilic…DexpramipexoleAreteia TherapeuticsClosed
May 9, 2025The imagine study: a phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with type 2…Depemokimab (GSK3511294)GSKOngoing
Dec 5, 2024Brisote: a multicentre, randomised, double-blind, parallel group, active-controlled, phase 3b study to evaluate the efficacy and safety of benralizumab 30 mg…Fasenra / Symbicort turbuhalerAstraZeneca PharmaceuticalsClosed
Nov 14, 2023A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for…DexpramipexoleAreteia TherapeuticsClosed
Nov 14, 2023A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for…DexpramipexoleAreteia TherapeuticsClosed
Dec 15, 2022A multicentre, randomised, double-blind, parallel group, placebo-controlled, time-to-first asthma exacerbation phase 3 efficacy and safety study of…FasenraAstraZeneca PharmaceuticalsClosed
May 28, 2021A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of…GSK3511294GSKOngoing
Mar 19, 2021A phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety, efficacy and pharmacodynamics of tev 53275…TEV-53275/ Proair digihalerTeva Pharmaceutical IndustriesClosed
Dec 17, 2020Efficacy of reslizumab dose escalation in patients with severe asthma and persistent sputum eosinophilia despite standard dose therapy.CinqairSt Josephs Hospital HamiltonOngoing
Jul 10, 2019A phase 4, multicenter, randomized, double-blind, parallel group, placebo controlled study to evaluate the effect of benralizumab on structural and lung…MEDI-563 (benralizumab)AstraZeneca PharmaceuticalsOngoing

Medicines authorised in the EU

Newest first
Jan 8, 2018FasenraBenralizumabAstraZeneca ABEMA ↗
Aug 15, 2016CinqaeroReslizumabTeva B.V.EMA ↗
Dec 1, 2015NucalaMepolizumabGlaxoSmithKline Trading Services LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.